/GNTA
GNTA Stock - Genenta Science S.p.A.
Healthcare|BiotechnologyNASDAQ
$1.45-2.03%
$0.03 (-2.03%) • Dec 19
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.97
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.59
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GNTA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.44 – $1.46
TARGET (TP)$1.67
STOP LOSS$1.33
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.57
52W High$10.00
52W Low$1.28
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-41,582 | $-6,029 | $-5,084 | $-1,770 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-9,764,310 | $-11,732,942 | $-11,043,992 | $-5,687,273 | $-5,590,226 |
| Net Income | $-8,912,495 | $-11,645,455 | $-8,477,763 | $-5,529,332 | $-5,605,734 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.49 | $-0.64 | $-0.47 | $-0.31 | $-0.31 |
Company Overview
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$20
Average Target
↑ 1279.3% Upside
Now
$15
Low
$20
Average
$25
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 29th 2023 | ROTH MKM | Resumed | Buy | $15 |
| July 25th 2022 | H.C. Wainwright | Initiation | Buy | $25 |
Earnings History & Surprises
GNTABeat Rate
100%
Last 3 quarters
Avg Surprise
+12.7%
EPS vs Estimate
Beats / Misses
3/0
Last 12 quarters
Latest EPS
$-0.42
Q4 2025
EPS Surprise History
Q4 21
No data
Q2 22
No data
Q4 22
No data
Q2 23
No data
Q2 23
+3.2%
$-0.40vs$-0.41
Q2 24
+29.7%
$-0.29vs$-0.42
Q2 24
No data
Q4 25
+5.3%
$-0.42vs$-0.45
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 10, 2025 | $-0.45 | $-0.42 | +5.3% | ✓ BEAT |
Q1 2025 | Mar 28, 2025 | $-0.26 | — | — | — |
Q2 2024 | Jun 30, 2024 | — | $-0.24 | — | — |
Q2 2024 | Apr 24, 2024 | $-0.42 | $-0.29 | +29.7% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-0.41 | $-0.40 | +3.2% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | — | $-0.38 | — | — |
Q4 2022 | Oct 7, 2022 | — | $-0.12 | — | — |
Q2 2022 | May 4, 2022 | — | $-0.11 | — | — |
Q4 2021 | Dec 15, 2021 | — | $-0.33 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.26 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.19 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.14 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.14 | — | — |
Latest News
Genenta Science Announced An Update From Its Ongoing TEM-GBM Study In Newly Diagnosed Glioblastoma Multiforme (GBM) Patients With An Unmethylated MGMT (uMGMT) Gene Promoter
➖ NeutralBenzinga•Nov 24, 2025, 09:02 AM
Genenta Science shares are trading lower after the company announced a $15 million registered direct offering of American Depositary Shares at $3.50 each.
📉 NegativeBenzinga•Oct 27, 2025, 02:53 PM
Genenta Science jumps on $15M direct offering
📈 PositiveSeeking Alpha•Oct 27, 2025, 07:20 AM
Reported Sunday, Genenta Prices $15M Registered Direct Offering Of ADSs At $3.50 Each To Support Working Capital And Corporate Growth
➖ NeutralBenzinga•Oct 27, 2025, 06:21 AM
Genenta Science shares are trading higher. The company extended its collaboration with Anemocyte to boost off-the-shelf genetic therapy production.
📈 PositiveBenzinga•Oct 24, 2025, 05:45 PM
Market-Moving News for October 24th
➖ NeutralBenzinga•Oct 24, 2025, 11:14 AM•Also: ,
Genenta Science Teams With Anemocyte To Enhance Off-The-Shelf Lentiviral Vector Plasmid DNA Platform Providing Reliable Materials From Preclinical To Commercial Applications
📈 PositiveBenzinga•Oct 24, 2025, 08:17 AM
Frequently Asked Questions about GNTA
What is GNTA's current stock price?
Genenta Science S.p.A. (GNTA) is currently trading at $1.45 per share. The stock has moved -2.03% today.
What is the analyst price target for GNTA?
No analyst price targets are currently available for this stock.
What sector is Genenta Science S.p.A. in?
Genenta Science S.p.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GNTA's market cap?
Genenta Science S.p.A. has a market capitalization of $0.03 billion, making it a small-cap company.
Does GNTA pay dividends?
No, Genenta Science S.p.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBRNS
Barinthus Biotherapeutics plc
$0.74
Mkt Cap: $0.0B
CVM
CEL-SCI Corporation
$4.91
Mkt Cap: $0.0B
INMB
INmune Bio, Inc.
$1.83
Mkt Cap: $0.0B
IPSC
Century Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
JUNS
Jupiter Neurosciences, Inc.
$1.10
Mkt Cap: $0.0B
MDCX
Medicus Pharma Ltd. Common Stock
$1.69
Mkt Cap: $0.0B
MRSN
Mersana Therapeutics, Inc.
$28.94
Mkt Cap: $0.1B
SER
Serina Therapeutics, Inc.
$2.75
Mkt Cap: $0.0B
SKYE
Skye Bioscience, Inc.
$0.93
Mkt Cap: $0.0B
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$1.41
Mkt Cap: $0.0B
Explore stocks similar to GNTA for comparison